Q2 Earnings Forecast for AnaptysBio Issued By HC Wainwright

Key Points

• HC Wainwright initiated Q2 2026 earnings coverage for AnaptysBio, projecting a loss of $0.84 per share and maintaining a Buy rating with a $95 price target.
• Other analysts remain generally positive on the stock, with AnaptysBio carrying a Moderate Buy consensus and an average price target of $81.82, though a couple firms recently downgraded it to Hold.
• AnaptysBio shares were up 4.1% and last traded at $54.24, while the company recently reported a wider-than-expected quarterly loss despite beating revenue estimates.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Stock analysts at HC Wainwright issued their Q2 2026 earnings estimates for shares of AnaptysBio in a research report issued on Wednesday, June 10th. HC Wainwright analyst J. Pantginis anticipates that the biotechnology company will earn ($0.84) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $95.00 target price on the stock. The consensus estimate for AnaptysBio's current full-year earnings is ($0.93) per share. HC Wainwright also issued estimates for AnaptysBio's Q3 2026 earnings at ($0.03) EPS, Q4 2026 earnings at $0.10 EPS, FY2026 earnings at ($2.60) EPS, FY2027 earnings at $2.86 EPS, FY2028 earnings at $5.42 EPS, FY2029 earnings at $6.20 EPS and FY2030 earnings at $7.64 EPS.

A number of other research firms have also weighed in on ANAB. Wall Street Zen lowered shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Saturday, May 16th. Leerink Partners set a $90.00 price target on shares of AnaptysBio in a research report on Friday, May 15th. UBS Group upped their price target on shares of AnaptysBio from $60.00 to $76.00 and gave the stock a "buy" rating in a research report on Wednesday, May 13th. Wedbush upped their price target on shares of AnaptysBio from $60.00 to $75.00 and gave the stock an "outperform" rating in a research report on Thursday, March 12th. Finally, Zacks Research lowered shares of AnaptysBio from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, June 2nd. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, AnaptysBio currently has an average rating of "Moderate Buy" and an average price target of $81.82.

AnaptysBio Trading Up 4.1%

AnaptysBio stock opened at $54.24 on Friday. The firm has a 50 day moving average of $60.35 and a 200 day moving average of $54.40. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -50.22 and a beta of 0.72. AnaptysBio has a 12-month low of $11.40 and a 12-month high of $72.36.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last released its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.84) EPS for the quarter, missing the consensus estimate of ($0.64) by ($1.20). AnaptysBio had a negative net margin of 11.53% and a negative return on equity of 1,101.24%. The business had revenue of $25.56 million for the quarter, compared to analysts' expectations of $18.86 million.

Institutional Trading of AnaptysBio

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Smartleaf Asset Management LLC increased its stake in AnaptysBio by 5,864.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company's stock worth $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 473 shares during the period. Bessemer Group Inc. increased its stake in AnaptysBio by 950.0% in the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 1,292 shares during the period. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 175.0% in the second quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 2,326 shares during the period.

Insider Buying and Selling at AnaptysBio

In related news, Director John P. Schmid sold 20,645 shares of the stock in a transaction on Monday, March 30th. The stock was sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the sale, the director owned 31,622 shares in the company, valued at approximately $1,774,310.42. This represents a 39.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Daniel Faga sold 17,679 shares of the stock in a transaction on Friday, March 27th. The shares were sold at an average price of $61.61, for a total value of $1,089,203.19. Following the sale, the chief executive officer owned 495,965 shares in the company, valued at $30,556,403.65. The trade was a 3.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 33.50% of the company's stock.

AnaptysBio announced that its board has authorized a share repurchase program on Friday, March 27th that allows the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization allows the biotechnology company to buy up to 5,352,316.2% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company's leadership believes its stock is undervalued.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company's technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company's pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.